{
    "clinical_study": {
        "@rank": "29943", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Citalor (Atorvastatin) - Pfizer"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide + Losartan", 
                "arm_group_type": "Active Comparator", 
                "description": "Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme"
            }, 
            {
                "arm_group_label": "Atorvastatin + Hydrochlorothiazide + Losartan", 
                "arm_group_type": "Experimental", 
                "description": "Polip\u00edlula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this clinical study, randomized, crossover is to evaluate the\n      pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide)\n      Laboratory Hypermarcas S / A, in relation to drugs Citalor \u00ae (atovastatina - Pfizer) and\n      Hyzaar \u00ae (losartan + hydrochlorothiazide - Merck Sharp & Dohme) by comparing the serum\n      concentration of analytes unchanged (AT, LS and HCTZ) in healthy subjects."
        }, 
        "brief_title": "Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Subjects", 
        "detailed_description": {
            "textblock": "The pharmacokinetic profile of the drug will also be assessed by comparing the serum\n      concentration of active metabolites following:\n\n        -  O-hydroxy atorvastatin (2-Hydroxy atorvastatin, O-HAT): metabolite of AT\n\n        -  carboxylic acid (E-3174, LS-CA): active metabolite of LS"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Confirm voluntary participation and agree to all the purposes of the study by signing\n             and dating the IC in two ways;\n\n          2. Age between 18 and 55 years, regardless of sex, clinically healthy and present\n             laboratory parameters within normal limits;\n\n          3. BMI \u2265 18.5 and \u2264 30.\n\n        Exclusion Criteria:\n\n          1. Participation in clinical trials in the 12 months preceding the survey;\n\n          2. History of hypersensitivity reactions to atorvastatin, losartan hydrochlorothiazide\n             and / or any other ingredients of medicines;\n\n          3. Alterations in clinical and laboratory criteria that interfere Principal Investigator\n             on the study results;\n\n          4. Presence of pulmonary diseases, cardiovascular, neurological, endocrine,\n             gastrointestinal, genitourinary or other systems;\n\n          5. Acute illness during the 07 days preceding the start of the study;\n\n          6. Chronic disease that determine drug delivery, such as hypertension, diabetes or any\n             other that requires continuous use of any medicine, including use of vitamins,\n             mineral supplements and OTCs (over-the-counter);\n\n          7. Having made regular use of medication in the last 02 weeks before the onset of the\n             study. The use of any medication that does not interfere with the physician's\n             judgment on the pharmacokinetics of the drug under study, will not be considered as\n             an exclusion criterion.\n\n          8. Use of medications that interact with any medications association;\n\n          9. History of or current use for at least 12 months of tobacco;\n\n         10. Current or previous history (under 12 months) of illicit drug use;\n\n         11. At the discretion of the Principal Investigator of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692717", 
            "org_study_id": "ALHHYP0512OR-I", 
            "secondary_id": "Vers\u00e3o 01 28.05.2012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Atorvastatin", 
                    "Hydrochlorothiazide + Losartan", 
                    "Atorvastatin + Hydrochlorothiazide + Losartan"
                ], 
                "description": "10 mg", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Citalor"
            }, 
            {
                "arm_group_label": [
                    "Atorvastatin", 
                    "Hydrochlorothiazide + Losartan", 
                    "Atorvastatin + Hydrochlorothiazide + Losartan"
                ], 
                "description": "12.5 mg + 50 mg", 
                "intervention_name": "Hydrochlorothiazide + Losartan", 
                "intervention_type": "Drug", 
                "other_name": "Hyzaar"
            }, 
            {
                "arm_group_label": [
                    "Atorvastatin", 
                    "Hydrochlorothiazide + Losartan", 
                    "Atorvastatin + Hydrochlorothiazide + Losartan"
                ], 
                "description": "12.5 mg + 50 mg + 10 mg", 
                "intervention_name": "Hydrochlorothiazide + Losartan + Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Polip\u00edlula"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Losartan", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 24, 2012", 
        "location": {
            "contact": {
                "email": "alexandre@lalclinica.com.br", 
                "last_name": "Alexandre Frederico, physician", 
                "phone": "55 19 38716399"
            }, 
            "facility": {
                "address": {
                    "city": "Valinhos", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo"
                }, 
                "name": "LAL Cl\u00ednica Pesquisa e Desenvolvimento Ltda"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "alexandre@lalclinica.com.br", 
            "last_name": "Alexandre Frederico, physician", 
            "phone": "55 19 38716399"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary pharmacokinetic parameters for the exercise of comparability will be unchanged dosages of analytes (AT, LS and HCTZ), assessed by AUC, Tmax, Cmax and T1 / 2.", 
            "safety_issue": "Yes", 
            "time_frame": "0h00, 0h15, 0h30, 0h45, 1h00, 1h15, 1h30, 1h45, 2h00, 2h30, 3h00, 3h30, 4h00, 4h30, 5h00, 6h00, 8h00, 10h00, 12h00, 18h00, 24h00, 36h00, 48h00, 56h00 e 72h00."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacokinetic parameters are side dosages of active metabolites O-HAT and E-3174, measured by AUC, Tmax, Cmax and T1 / 2.", 
            "safety_issue": "Yes", 
            "time_frame": "0h00, 0h15, 0h30, 0h45, 1h00, 1h15, 1h30, 1h45, 2h00, 2h30, 3h00, 3h30, 4h00, 4h30, 5h00, 6h00, 8h00, 10h00, 12h00, 18h00, 24h00, 36h00, 48h00, 56h00 e 72h00."
        }, 
        "source": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}